ArticleBlood advances2021

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.

Arnon P Kater et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.